
Nextcure (NXTC) Stock Forecast & Price Target
Nextcure (NXTC) Analyst Ratings
Bulls say
NextCure Inc. has secured global rights to SIM0505 outside of Greater China, which could yield up to $745 million in upfront and milestone payments, alongside tiered royalties that could reach double-digit percentages on net sales. The company is also focusing on its ADCs, which are projected to contribute positively despite a reassessment of other product candidates, reflecting a strategic pivot that enhances their overall value. Promising preclinical data indicates robust anti-tumor activity and a favorable safety profile for SIM0505, further supporting NextCure's strong pipeline and potential for future growth.
Bears say
NextCure Inc. has experienced a significant reduction in its projected enterprise value, which has decreased from $75 million to $37.5 million, contributing to a lower price target of $15. The clinical-stage biopharmaceutical company faces inherent risks associated with its therapies, including the potential for those therapies to fail during clinical trials. Additionally, the company's need to seek partnerships for its various programs may indicate challenges in securing necessary funding and support, further compounding the negative outlook on its stock.
This aggregate rating is based on analysts' research of Nextcure and is not a guaranteed prediction by Public.com or investment advice.
Nextcure (NXTC) Analyst Forecast & Price Prediction
Start investing in Nextcure (NXTC)
Order type
Buy in
Order amount
Est. shares
0 shares